Even though the clinical relevance with the aforementioned cardiovascular hazard factor alterations by tirzepatide might be assessed inside the planned cardiovascular result examine SURPASS-CVOT ( "type":"medical-trial","attrs": "textual content":"NCT04255433","term_id":"NCT04255433" NCT04255433), a pre-specified cardiovascular meta-Investigation i